Please login to the form below

Not currently logged in

Generex publishes Oral-Lyn study

Generex has published the results of a Oral-lyn study in the Diabetes Technology & Therapeutics journal covering new technology and products for the treatment, monitoring, diagnosis and prevention of diabetes

Generex Biotechnology, a US developer of buccal drug delivery for metabolic diseases, has published the results of a Oral-lyn study in Diabetes Technology & Therapeutics, a peer-reviewed journal covering new technology and products for the treatment, monitoring, diagnosis and prevention of diabetes.

Oral-lyn buccal spray uses Generex's proprietary drug delivery technology, RapidMist, which administers medications directly into the mouth as a metered-dose spray, for rapid absorption by the buccal mucosa.

The study, entitled 'Comparison of Oral Insulin Spray and Subcutaneous Regular Insulin at Mealtime in Type 1 Diabetes' was led by Dr Jaime Guevara-Aguirre, Dr Marco Guevara-Aguirre, Dr Jeannette Saavedra, Dr Gerald Bernstein and Dr Arlan L Rosenbloom.

The results of the study showed that regular insulin and Oral-lyn had similar glucodynamic effects in subjects with type 1 diabetes receiving a twice-daily insulin analogue as baseline therapy.

Monitoring and baseline corrections with additional snacks, subcutaneous regular insulin or Generex Oral-lyn puffs resulted in glycaemic control as assessed by individual daily glycaemic responses, while normal pre-prandial glycation decreased, but not significantly.

Dr Gerald Bernstein, Generex's vice-president of medical affairs and a co-author of the article, said: "This publication is significant in that it shows consistently and clearly that equivalent amounts of Generex Oral-lyn and injected regular insulin will yield comparable blood glucose control."

Generex launched Oral-Lyn in South America in 2005.

16th August 2007


Subscribe to our email news alerts


Add my company
Twist Health

Not just another healthcare communications agency. We are a collection of award-winning industry experts focusing on bringing the very best...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....